CEO COMMENTS
Kristina Torfgård comments Q3 report 2025
“In recent months, we have taken several important steps in the development of our leading drug projects. Preparations for the Phase Ib study of IRL757 are progressing according to plan, and we have strengthened the commercial position of mesdopetam through new patent protection. During the quarter, a rights issue was carried out, providing the necessary capital and resources for the continued development of our drug candidates IRL1117 and pirepemat. We are also pleased to welcome Gustaf Albèrt as our new CFO, and the management team now continues to execute our strategy with full focus and determination.
Key Milestones During the Quarter and after:
- IRLAB’s partner MSRD issued a payment of USD 4 million for the fully funded study of IRL757 in Parkinson’s disease, which is progressing according to plan.
- An application to initiate a Phase Ib study of IRL757 in individuals with Parkinson’s disease and apathy was submitted to the EMA, and patient recruitment is expected to begin by the end of 2025.
- The recently granted patent for mesdopetam in China further strengthens the already robust patent and exclusivity protection, with potential market exclusivity well into the 2040s in all major markets.
- The rights issue has provided resources for the next development phase of two of IRLAB’s unique drug projects, IRL1117 and pirepemat – with the manufacturing of the drug substance now initiated.
Together, these advances demonstrate that IRLAB is well on its way to realizing its vision and creating value for patients, partners, and shareholders.”
LATEST INTERIM REPORTS
LATEST ANNUAL REPORT
IRLAB has received scientific advisory board confirmation on next steps for pirepemat
Gothenburg, Sweden, February 20, 2026. IRLAB Therapeutics (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that its scientific advisory board has provided important guidance on the continued development and plans for its drug candidate, pirepemat. The advisory board concludes that the pharmacological rationale for pirepemat is sensible and that the reduction in falls observed in the Phase IIb trial is clinically meaningful, warranting further development.
Read More >
Q&A session with Kristina Torfgård, CEO and Nicholas Waters, EVP, Head of R&D, at Redeye Technology & Life Science Day
Kristina Torfgård, CEO, and Nicholas Waters, EVP, Head of R&D, participated in the Redeye Technology & Life Science Day on December 3, 2025. https://www.redeye.se/video/event-presentation/1130614/irlab-therapeuti%E2%80%A6-2025-october-15?embed
Read More >FINANCIAL CALENDAR
NEXT
February 25, 2026
Year-end report 2025